Close button Adverse Events image
Close button

For further information, please consult the approved ▼CAMZYOS
Summary of the Product Characteristics available at the booth

Prescribing Information also available here:

Scan the QR code to view

3500-ES-2500034 08/2025

References

Prescribing Information

Home

Close button

References:

  • 1.Ho CY, Day SM, Ashley EA, Michels M, Pereira AC, Jacoby D, et al. Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe). Circulation. 2018;138(14):1387-98.
  • 2.Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P, et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy. Circulation. 2020;142(25):e558-631.
  • 3.Zaiser E, Sehnert AJ, Duenas A, Saberi S, Brookes E, Reaney M, et al. Patient experiences with hypertrophic cardiomyopathy: a conceptual model of symptoms and impacts on quality of life. J Patient Rep Outcomes. 2020;4(1):102.
  • 4.Bristol Myers Squibb. CAMZYOS (mavacamten) Summary of Product Characteristics.
  • 5.Olivotto I, Oreziak A, Barriales-Villa R, Abraham TP, Masri A, Garcia-Pavia P, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020;396(10253):759-69.